BR112016016700A2 - Composição para acelerar a penetração através da pele, preparação para administração transdérmica, e preparação de emplastro de pele - Google Patents

Composição para acelerar a penetração através da pele, preparação para administração transdérmica, e preparação de emplastro de pele

Info

Publication number
BR112016016700A2
BR112016016700A2 BR112016016700A BR112016016700A BR112016016700A2 BR 112016016700 A2 BR112016016700 A2 BR 112016016700A2 BR 112016016700 A BR112016016700 A BR 112016016700A BR 112016016700 A BR112016016700 A BR 112016016700A BR 112016016700 A2 BR112016016700 A2 BR 112016016700A2
Authority
BR
Brazil
Prior art keywords
skin
preparation
composition
penetration
accelerating
Prior art date
Application number
BR112016016700A
Other languages
English (en)
Inventor
Matsushita Kyohei
Maeda Yoshiki
Li Wenjing
Okubo Katsuyuki
Hori Mitsuhiko
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of BR112016016700A2 publication Critical patent/BR112016016700A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÃO PARA ACELERAR A PENETRAÇÃO ATRAVÉS DA PELE, PREPARAÇÃO PARA ADMINISTRAÇÃO TRANSDÉRMICA, E PREPARAÇÃO DE EMPLASTRO DE PELE. A presente invenção trata-se de uma composição para acelerar a penetração através da pele, que pode melhorar significativamente a penetração de um medicamento através da pele sem exigir a conformação do medicamento em uma estrutura particulada ou semelhante, e sem causar dano aos tecidos dérmicos. Também é fornecida uma preparação para administração transdérmica e uma preparação de emplastro de pele, em que cada uma contém a composição para acelerar a penetração através da pele. Além disso, também é provida uma composição para acelerar a penetração através da pele, que contém um composto flavonoide e um tensoativo, e pode ser usada para acelerar a penetração de um medicamento através da pele.
BR112016016700A 2014-01-29 2015-01-28 Composição para acelerar a penetração através da pele, preparação para administração transdérmica, e preparação de emplastro de pele BR112016016700A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014014540 2014-01-29
PCT/JP2015/052389 WO2015115496A1 (ja) 2014-01-29 2015-01-28 皮膚透過促進組成物、経皮投与製剤及び貼付製剤

Publications (1)

Publication Number Publication Date
BR112016016700A2 true BR112016016700A2 (pt) 2017-08-08

Family

ID=53757069

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016016700A BR112016016700A2 (pt) 2014-01-29 2015-01-28 Composição para acelerar a penetração através da pele, preparação para administração transdérmica, e preparação de emplastro de pele

Country Status (9)

Country Link
US (1) US20170007703A1 (pt)
EP (1) EP3100743A4 (pt)
JP (1) JP2015163605A (pt)
KR (1) KR20160106181A (pt)
CN (1) CN105992596A (pt)
BR (1) BR112016016700A2 (pt)
CA (1) CA2937534A1 (pt)
RU (1) RU2016134903A (pt)
WO (1) WO2015115496A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9929048B1 (en) * 2016-12-22 2018-03-27 Globalfoundries Inc. Middle of the line (MOL) contacts with two-dimensional self-alignment
EP3898089A1 (en) 2018-12-18 2021-10-27 3M Innovative Properties Company Coated abrasive articles and methods of making coated abrasive articles

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936611A (ja) * 1982-08-26 1984-02-28 Nitto Electric Ind Co Ltd 粘着性貼付製剤
JPS5955822A (ja) * 1982-09-24 1984-03-31 Nitto Electric Ind Co Ltd 粘着性貼付製剤用膏体
JPS6137304A (ja) 1984-07-31 1986-02-22 Nippon Steel Corp 傾斜ロ−ル圧延機
JPH0429934A (ja) * 1990-05-28 1992-01-31 Seiichi Umeda いちょう葉抽出エキスを含有する外用組成物
US5702720A (en) * 1995-12-22 1997-12-30 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of flurbiprofen
JPH10139690A (ja) * 1996-11-02 1998-05-26 Shinichi Konuma 経皮吸収促進剤
JP4073517B2 (ja) 1997-04-07 2008-04-09 久光製薬株式会社 経皮吸収貼付剤用粘着剤及び経皮吸収貼付剤
TW492882B (en) * 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US20030175333A1 (en) * 2002-03-06 2003-09-18 Adi Shefer Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin
JP4027850B2 (ja) * 2003-06-20 2007-12-26 ポーラ化成工業株式会社 経皮吸収促進化粧料
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
EP1867323A1 (en) * 2006-06-13 2007-12-19 Farmatron Ltd. Pharmaceutical compositions with biological barriers permeation enhancing properties
JP5224770B2 (ja) 2007-03-19 2013-07-03 金印株式会社 コラーゲン産生促進剤、促進方法、香粧品、飲食品および医薬品
BR112012011336A2 (pt) * 2009-10-22 2018-10-16 Api Genesis Llc Composições compreendendo flavonoides, seu método de preparação, adesivo para aplicação de flavonoide, métodos de produção de flavonoide hidratado,métodos de preparação de formulação tópica, e uso de flavonoide
KR101817635B1 (ko) * 2010-10-22 2018-01-11 비쭈리 헬스 사이언스 엘엘씨 난용성 화합물의 용해도를 증가시키는 방법과 이와 같은 화합물의 제형을 제조하는 방법 및 사용하는 방법
JP2012206979A (ja) 2011-03-30 2012-10-25 Ssp Co Ltd 経皮投与用医薬組成物
JP5856424B2 (ja) 2011-10-05 2016-02-09 祐徳薬品工業株式会社 ロチゴチン含有経皮吸収型貼付剤

Also Published As

Publication number Publication date
EP3100743A1 (en) 2016-12-07
US20170007703A1 (en) 2017-01-12
CN105992596A (zh) 2016-10-05
KR20160106181A (ko) 2016-09-09
WO2015115496A1 (ja) 2015-08-06
EP3100743A4 (en) 2017-08-30
JP2015163605A (ja) 2015-09-10
RU2016134903A (ru) 2018-03-01
CA2937534A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
IL264413B (en) Preparations containing fibers obtained electrohydrodynamically for delivering specific doses of active substance to the skin or mucous membrane
CO2018006714A2 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
GT201500011A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
IN2014MN02214A (pt)
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
BR112017006113A2 (pt) combinações sinérgicas de auristatina
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
TW201613578A (en) Pharmaceutical combinations
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
EP3265060A4 (en) Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
CO2018004665A2 (es) Compuestos oxadiazoespíricos
BR112016017496A2 (pt) Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]